Teva Begins Phase IV Clinical Trial of Azilect for Treatment of Mild Cognitive Impairment in Patients Living with Parkinsonís Disease
(February 7, 2013) – Teva will evaluate the cognitive function in adults living with Parkinson’s disease who experience mild cognitive impairment. Their Phase IV study will study the impact of Azilect on these symptoms. They believe this will potentially meet an unmet need, since there are no treatments presently available for cognitive impairment in PD.
Read the press release from Teva Pharmaceuticals for more information.